First Financial Corp IN Maintains Holdings in Bristol-Myers Squibb Company (BMY)
First Financial Corp IN continued to hold its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,550 shares of the biopharmaceutical company’s stock at the end of the second quarter. First Financial Corp IN’s holdings in Bristol-Myers Squibb were worth $643,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in BMY. Naples Global Advisors LLC grew its stake in Bristol-Myers Squibb by 0.6% in the first quarter. Naples Global Advisors LLC now owns 16,371 shares of the biopharmaceutical company’s stock worth $890,000 after purchasing an additional 95 shares in the last quarter. Murphy Pohlad Asset Management LLC grew its stake in Bristol-Myers Squibb by 5.8% in the first quarter. Murphy Pohlad Asset Management LLC now owns 18,288 shares of the biopharmaceutical company’s stock worth $994,000 after purchasing an additional 1,000 shares in the last quarter. Patriot Wealth Management Inc. bought a new position in Bristol-Myers Squibb in the first quarter worth approximately $3,984,000. Boyd Watterson Asset Management LLC OH bought a new position in Bristol-Myers Squibb in the first quarter worth approximately $212,000. Finally, Nicolet Bankshares Inc. grew its stake in Bristol-Myers Squibb by 73.5% in the first quarter. Nicolet Bankshares Inc. now owns 17,960 shares of the biopharmaceutical company’s stock worth $977,000 after purchasing an additional 7,606 shares in the last quarter. 68.88% of the stock is currently owned by institutional investors.
BMY has been the topic of several research analyst reports. Cowen and Company reissued a “hold” rating and issued a $65.00 price objective on shares of Bristol-Myers Squibb in a research note on Tuesday, September 19th. Jefferies Group LLC increased their price objective on Bristol-Myers Squibb from $66.00 to $72.00 and gave the stock a “buy” rating in a research note on Monday, September 11th. Vetr cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $63.67 price objective on the stock. in a research note on Thursday. Hilliard Lyons cut Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective on the stock. in a research note on Tuesday, September 12th. Finally, Goldman Sachs Group, Inc. (The) reissued a “buy” rating and issued a $63.00 price objective on shares of Bristol-Myers Squibb in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $62.17.
In related news, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total value of $560,400.00. Following the completion of the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Theodore R. Samuels II purchased 6,000 shares of Bristol-Myers Squibb stock in a transaction that occurred on Wednesday, August 2nd. The stock was bought at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the transaction, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Shares of Bristol-Myers Squibb Company (BMY) traded up 1.16% during mid-day trading on Friday, hitting $63.74. The stock had a trading volume of 5,404,324 shares. The stock’s 50-day moving average is $58.94 and its 200 day moving average is $56.02. The firm has a market cap of $104.53 billion, a PE ratio of 23.28 and a beta of 1.18. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $63.75. Bristol-Myers Squibb also was the recipient of unusually large options trading activity on Thursday. Stock investors bought 781 put options on the company. This represents an increase of approximately 117% compared to the typical volume of 360 put options.
Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 EPS for the quarter, topping analysts’ consensus estimates of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to the consensus estimate of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.69 earnings per share. Equities research analysts predict that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Investors of record on Friday, October 6th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, October 5th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.45%. Bristol-Myers Squibb’s payout ratio is currently 56.73%.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with Analyst Ratings Network's FREE daily email newsletter.